发明名称 Cytotoxic T lymphocyte-mediated immunotherapy
摘要 The present invention is directed to methods for stimulating primary and secondary effector cell responses for cellular immunotherapy. Cellular immunotherapy can successfully prevent or treat various viral infections and tumors, such as posttransplant EBV lymphoma. The present invention offers a general method for effecting cellular immunotherapy by providing for presentation, by the most effective antigen presenting cells, viral particles or specific antigens, without the need to develop an active viral infection in the antigen presenting cells. Furthermore, the present invention provides for generating effector cells against more than one opportunistic pathogen, e.g., Epstein-Barr virus and adenovirus. The effector cells generated according to the invention, which include CD4 and CD8 cells, are extremely long lived in vivo after adoptive transfer. In specific embodiments, dendritic cells present whole adenovirus particles via class I MHC molecules, transduced dendritic cells present a weak EBV antigen to effector cells, and EBV-transformed lymphoblastoid cells present whole adenoviral particles to effector cells, generating a population of effector cells active against EBV and adenovirus. Moreover, the adenovirus-specific effector cells of the present invention, generated against one adenovirus subgroup, recognize different adenovirus subgroups.
申请公布号 US5962318(A) 申请公布日期 1999.10.05
申请号 US19960746726 申请日期 1996.11.15
申请人 ST. JUDE CHILDREN'S RESEARCH HOSPITAL 发明人 ROONEY, CLIONA;ROSKROW, MARIE;KITCHINGMAN, GEOFFREY;SMITH, COLTON
分类号 A61K39/00;A61K48/00;C12N5/0783;(IPC1-7):A01N63/00;C12N5/00 主分类号 A61K39/00
代理机构 代理人
主权项
地址